Long-term efficacy and safety of Control-IQ technology in younger children with type 1 diabetes in Italy (2020-2023): a longitudinal multicentre real-world study [0.03%]
意大利（2020-2023年）T1D年轻儿童使用Control-IQ技术的长期有效性和安全性：纵向多中心真实世界研究
Valentino Cherubini,Roberto Franceschi,Andrea Fargalli et al.
Valentino Cherubini et al.
Background: Automated insulin delivery (AID) systems have demonstrated significant improvements in glycemic control in children and adults with type 1 diabetes, but long-term real-world data in preschool-aged children rem...
Effectiveness of brief interventions and contacts after suicide attempt: a systematic review and meta-analysis [0.03%]
自杀未遂后的简短干预和随访的有效性：系统综述和meta分析
Stephanie Homan,Marta Anna Marciniak,Sofia Michel et al.
Stephanie Homan et al.
Background: Following a suicide attempt, only a third of people receive outpatient treatment, highlighting the need for low-threshold brief interventions and contacts (BICs). We aimed to examine the effectiveness of BICs....
Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis [0.03%]
stride水平测量在多发性硬化症患者的残疾进展中的早期敏感标志
Margaux Poleur,Barbara Willekens,Bertrand Degos et al.
Margaux Poleur et al.
Background: Wearable digital health technologies offer a unique opportunity to assess gait at the stride level in real-world settings. Walking impairment is a major cause of disability in multiple sclerosis (MS), yet curr...
Two-year follow-up of neuropsychiatric symptoms in patients with systemic autoimmune rheumatic diseases: longitudinal insights on depression, anxiety, memory and adaptation in the INSPIRE cohort [0.03%]
ANZRHNC 2021 - 抑郁、焦虑、记忆和适应能力在INSPIRE队列中的纵向研究：系统性自身免疫风湿病患者的两年随访结果
Melanie Sloan,Avni Varshney,David D&#x;Cruz et al.
Melanie Sloan et al.
Background: To date, studies of neuropsychiatric symptoms in systemic autoimmune rheumatic diseases (SARDs) have largely been cross-sectional. Our longitudinal study with patients with SARDs from the international INSPIRE...
Burden of non-communicable diseases among adolescents and young adults aged 10-24 years in Middle East and North Africa, 1990-2023: a systematic analysis of the Global Burden of Diseases Study 2023 [0.03%]
1990年至2023年中东和北非地区10至24岁青少年及年轻人非传染性疾病负担：《2023年全球疾病负担研究》系统分析结果
Dian Kusuma,Abrari Noor Hasmi,Ankita Shukla et al.
Dian Kusuma et al.
Background: Non-communicable diseases (NCDs) are a major contributor to morbidity and mortality worldwide, yet their burden among adolescents and young adults in the Middle East and North Africa (MENA) region remains unde...
Retraction Notice to "Effect of subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin (HP-β-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study" [eClinicalMedicine 90(2025) 103681] [0.03%]
关于“局部利多卡因-羟丙基β环糊精对新冠后遗症患者生活质量的影响：一项36周观察性中断时间序列研究”的撤稿声明[eClinicalMedicine 90(2025) 103681]
Cees-Jan Oostwouder,Karin Vos,Ivo J Lutke Schipholt et al.
Cees-Jan Oostwouder et al.
[This retracts the article DOI: 10.1016/j.eclinm.2025.103681.]. © 2026 The Author(s).
Reliable classification of polyps based on artificial intelligence: a development and validation study [0.03%]
基于人工智能的可靠息肉分类：一项发展与验证研究
Frida M I Julbø,Audun L Henriksen,Manohar Pradhan et al.
Frida M I Julbø et al.
Background: The shortage of pathologists presents a significant bottleneck in delivering timely and accurate diagnoses. To address this challenge, we developed the POLyp Artificial Intelligence-based RISk classifier (POLA...
Real-world effectiveness of antiretroviral backbone regimens on viral suppression in pediatric and adolescent HIV care: a six-year cohort study from Uganda [0.03%]
抗逆转录病毒主蛋白抑制剂方案在儿童和青少年人类免疫缺陷病毒感染治疗中的实际效果：来自乌干达的一项为期六年的队列研究
Collins Ankunda,Brendah Kyomuhangi,Jude Emunyu et al.
Collins Ankunda et al.
Background: Optimizing nucleoside reverse transcriptase inhibitor (NRTI) backbones is vital for pediatric and adolescent HIV treatment, yet real-world comparative evidence is limited. This study assessed backbone regimen ...
Corrigendum to 'Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial' eClinicalMedicine 2026; 92: 103764 [0.03%]
有关“用于治疗与Modic I型变化相关的慢性下背痛的椎间盘内线扎霉素（PP353）的研究：一项国际性首次人体、随机分组、假手术对照、双盲一期临床试验”的勘误*eClinicalMedicine* 2026; 92: 103764
Michael R Lassen,Matthew Scarborough,Nigel Gilchrist et al.
Michael R Lassen et al.
[This corrects the article DOI: 10.1016/j.eclinm.2026.103764.]. © 2026 The Author(s).
Published Erratum
EClinicalMedicine. 2026 Mar 12:93:103834. DOI:10.1016/j.eclinm.2026.103834 2026
Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trial [0.03%]
一项国际多中心随机双盲安慰剂对照的IIa期临床试验：每日一次口服ritlecitini或brepocitinib治疗中至重度活动性克罗恩病（PIZZICATO）
Severine Vermeire,Jessica R Allegretti,Hyo Jong Kim et al.
Severine Vermeire et al.
Background: Crohn's disease (CD) has a high unmet need for treatment. Ritlecitinib (Janus Kinase [JAK]3/tyrosine kinase expressed in hepatocellular carcinoma [TEC] family kinase inhibitor) or brepocitinib (tyrosine kinase...